Investors ‘beginning to appreciate’ scale of biotech market opportunity
Biotechnology companies have emerged from the COVID pandemic in “healthy if not robust” shape and...
Biotechnology companies have emerged from the COVID pandemic in “healthy if not robust” shape and...
One of the leading clinical-stage oncology companies, Prescient Therapeutics Limited (ASX:PTX), has been making its...
Prescient Therapeutics Limited (ASX: PTX) has released the results for September quarter of fiscal year...
Prescient Therapeutics (PTX) says it is poised to reach value-adding milestones across its anti-cancer programs...
Summary Prescient Therapeutics (ASX:PTX): We spoke with Steve Yatomi-Clarke, CEO of Prescient Therapeutics, about the exciting new...
Prescient Therapeutics (ASX: PTX) CEO Steven Yatomi-Clarke recently presented at the AusBiotech Investment Conference 2021....
Prescient Therapeutics’ next-generation CAR-T platform OmniCAR has delivered overwhelmingly positive results in recent pre-clinical studies...
(ASX:PTX) is presenting new preclinical data on OmniCAR at the Cell and Gene Meeting in...
Clinical-stage oncology company Prescient Therapeutics (ASX: PTX) has revealed new data that demonstrates the capability of its...
Prescient’s OmniCAR platform could overcome the limitations of CAR-T treatments for cancer and it’s attracting...
This investor centre was built by Reach Markets
©2022 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.